SVB Leerink lowered shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) from an outperform rating to a market perform rating in a report released on Tuesday, PriceTargets.com reports.
Several other brokerages also recently weighed in on DICE. Guggenheim downgraded shares of DICE Therapeutics from a buy rating to a neutral rating in a report on Wednesday. Cowen began coverage on shares of DICE Therapeutics in a report on Wednesday, March 1st. They set an outperform rating on the stock. Cantor Fitzgerald downgraded shares of DICE Therapeutics from an overweight rating to a neutral rating in a report on Tuesday. SVB Securities downgraded shares of DICE Therapeutics from an outperform rating to a market perform rating in a report on Wednesday. Finally, TD Cowen began coverage on shares of DICE Therapeutics in a report on Wednesday, March 1st. They set an outperform rating on the stock. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and an average price target of $63.60.
DICE Therapeutics Stock Up 0.0 %
Shares of NASDAQ:DICE opened at $46.61 on Tuesday. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -21.38 and a beta of 0.69. The firm’s 50-day simple moving average is $34.26 and its 200-day simple moving average is $31.46. DICE Therapeutics has a fifty-two week low of $14.41 and a fifty-two week high of $46.75.
Insider Activity
In other news, insider John R. Jacobsen sold 16,392 shares of the business’s stock in a transaction that occurred on Tuesday, April 18th. The shares were sold at an average price of $30.08, for a total value of $493,071.36. Following the completion of the transaction, the insider now owns 166,247 shares of the company’s stock, valued at $5,000,709.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider John R. Jacobsen sold 16,392 shares of the business’s stock in a transaction that occurred on Tuesday, April 18th. The shares were sold at an average price of $30.08, for a total value of $493,071.36. Following the completion of the sale, the insider now directly owns 166,247 shares in the company, valued at $5,000,709.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ra Capital Management, L.P. bought 151,132 shares of the stock in a transaction that occurred on Monday, March 27th. The stock was bought at an average price of $27.48 per share, with a total value of $4,153,107.36. Following the completion of the acquisition, the director now owns 6,561,060 shares of the company’s stock, valued at approximately $180,297,928.80. The disclosure for this purchase can be found here. Insiders sold a total of 162,960 shares of company stock valued at $5,893,009 over the last 90 days. Insiders own 4.90% of the company’s stock.
Institutional Investors Weigh In On DICE Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY grew its holdings in DICE Therapeutics by 20.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,223 shares of the company’s stock valued at $69,000 after purchasing an additional 375 shares during the period. Metropolitan Life Insurance Co NY grew its stake in DICE Therapeutics by 20.3% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,223 shares of the company’s stock worth $69,000 after buying an additional 375 shares during the period. Arizona State Retirement System grew its stake in DICE Therapeutics by 5.4% during the first quarter. Arizona State Retirement System now owns 8,978 shares of the company’s stock worth $257,000 after buying an additional 463 shares during the period. Alliancebernstein L.P. grew its stake in DICE Therapeutics by 3.1% during the fourth quarter. Alliancebernstein L.P. now owns 26,900 shares of the company’s stock worth $839,000 after buying an additional 800 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in DICE Therapeutics by 17.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,426 shares of the company’s stock worth $155,000 after buying an additional 812 shares during the period.
About DICE Therapeutics
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics.
Featured Stories
- Get a free research report on DICE Therapeutics from StockNews.com
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Darden Restaurants: Ring The Register Or Time To Buy?
- United Airlines: Cleared For Takeoff As It Approaches Buy Point?
- KB Home Hits Peak: Pullback Imminent
- Five stocks we like better than DICE Therapeutics
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
